Insurance Benefits for End-of-Life Care Outside Hospitals... Reimbursement for "Home Hospice" Increased
Ministry of Health and Welfare Holds Second 2026 Policy Committee Meeting
Decision Made to Increase Reimbursement for Home Visits and End-of-Life Care
New Health Insurance Coverage for PetrozaJu and Other Drugs
Health insurance coverage for home-based hospice care, which helps terminally ill patients prepare for the end of life at home rather than in a hospital, will be strengthened.
The Ministry of Health and Welfare held the 2nd Health Insurance Policy Deliberation Committee (HIPDC) meeting of 2026 on January 29 and discussed these measures.
First, starting March 1, the reimbursement rates for home-based hospice care will be increased. Hospice care is a medical service that provides physical, psychosocial, and spiritual assessment and treatment?including pain and symptom management?to terminally ill or dying patients and their families. Eligible patients include those with cancer, acquired immunodeficiency syndrome (AIDS), chronic obstructive pulmonary disease, chronic liver cirrhosis, and chronic respiratory failure.
Home-based hospice care involves hospice teams from specialized hospitals visiting patients' homes to provide hospice services. As of September last year, a total of 2,042 patients were using this service. The Ministry plans to increase reimbursement rates for ongoing patient management services, such as home visits by doctors, nurses, and social workers, as well as end-of-life care and telephone counseling, thereby strengthening overall compensation for home-based hospice care.
The Ministry stated, "As Korea enters a super-aged society, we plan to expand the provision of home-based hospice care by increasing reimbursement rates, so that terminally ill and dying patients can end their lives with dignity in their own homes, ensuring care until the very last moment."
At the HIPDC meeting, other topics discussed included: ▲ revision of the drug reimbursement list and maximum reimbursement prices ▲ revision of the health insurance service reimbursement and non-reimbursement lists and relative value scores ▲ 2026 performance support for the restructuring of tertiary general hospitals and strengthening of essential specialized functions ▲ and plans to promote performance-based support for comprehensive secondary general hospitals.
Starting next month, health insurance coverage will be extended to two new drugs: 'Petroza Injection' (ingredient: cefiderocol tosilate sulfate hydrate) and 'Rejurok Tablet' (ingredient: belumosudil mesylate). Petroza Injection is an antimicrobial agent with the broadest spectrum among currently developed antibiotics for gram-negative bacteria, effective not only against most gram-negative bacteria but also multidrug-resistant strains. Rejurok Tablet is a third-line treatment for chronic graft-versus-host disease. Since there are currently no established therapies or drugs for third-line treatment, its inclusion is expected to expand treatment opportunities for patients.
The results were also finalized for five drug ingredients that were selected for additional discussion among those targeted for the '2025 Drug Reimbursement Appropriateness Reassessment' decided at last year's 24th HIPDC meeting. First, old-type activated charcoal and Artemisia extract were evaluated as cost-effective compared to alternative drugs due to voluntary price reduction requests from pharmaceutical companies, so reimbursement will be maintained at the reduced price. For oral L-aspartate-L-ornithine, reimbursement will be limited to hepatic encephalopathy, and maintained for this indication only. For three ingredients, including seleglycotide, which are undergoing clinical re-evaluation by the Ministry of Food and Drug Safety, the assessment was deferred on the condition that part of the reimbursement will be clawed back if efficacy is not proven.
Performance support will also be provided this year to medical institutions selected for the 'Tertiary General Hospital Restructuring Support Project' and the 'Essential Specialized Function Enhancement Support Project,' which aim to strengthen regional and essential healthcare. For the Tertiary General Hospital Restructuring Support Project, now in its second year, five new performance indicators will be introduced, reflecting improvements from last year's project evaluation: ▲ volume of outpatient follow-up visits ▲ referrals and returns with comprehensive secondary general hospitals and specialists ▲ proportion of severe and high-difficulty patient care (Q3-Q4) ▲ patient satisfaction ▲ and operation and results of multi-institutional training networks. Performance indicators for the Essential Specialized Function Enhancement Support Project are mainly divided into maintaining a 24-hour care system, emergency response, and strengthening care collaboration.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Performance-based support will also be implemented to encourage positive changes among institutions participating in the comprehensive secondary general hospital support project. Approximately 200 billion won will be provided annually to comprehensive secondary general hospitals so they can focus on providing emergency and collaborative care for patients with appropriate conditions. The performance indicators will be supplemented and developed each year, considering project implementation and policy needs. This year, the evaluation will focus on the proportion of patients with appropriate conditions, proportion of local patients, emergency care outcomes, and achievements in collaborative care.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.